Stroke associated with atrial fibrillation

Fernando Testai MD PhD (

Dr. Testai of The University of Illinois College of Medicine has no relevant financial relationship to disclose.

Gabriela Trifan MD (

Dr. Trifan of The University of Illinois College of Medicine has no relevant financial relationship to disclose.

Steven R Levine MD, editor. (

Dr. Levine of the SUNY Health Science Center at Brooklyn has no relevant financial relationships to disclose.

Originally released June 20, 1996; last updated December 3, 2019; expires December 3, 2022

This article includes discussion of stroke associated with atrial fibrillation and cardioembolic stroke. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.


Stroke is the leading cause of disability in United States. Cardioembolism is a particularly disabling stroke subtype that accounts for 20% to 30% of all stroke cases. Observational studies demonstrated that almost half of the cardioembolic strokes are related to atrial fibrillation. In this article, the authors discuss the association of atrial fibrillation with stroke, the role of anticoagulation in stroke prevention, the available risk stratification tools, and the pathogenic mechanisms of thrombus formation associated with this cardiac arrhythmia.

Key points


• Atrial fibrillation confers a 3- to 5-fold increase in stroke risk and accounts for 15% to 30% of all ischemic strokes.


• Prolonged cardiac monitoring is superior to short-term monitoring for the detection of occult atrial fibrillation.


• Patients with atrial fibrillation and a CHA2DS2-VASc score of 0 in men and 1 in women have a low stroke risk and do not require treatment with antithrombotics.


• Patients with atrial fibrillation and a CHA2DS2-VASc score of 1 in men and 2 in women have an intermediate stroke risk and can potentially be treated with oral anticoagulants.


• Patients with atrial fibrillation and a CHA2DS2-VASc score of 2 or higher in men and 3 or higher in women are at high risk for stroke and should be offered treatment with anticoagulants.


• Direct thrombin or factor Xa inhibitors are not inferior to warfarin in the prevention of stroke or systemic embolism in atrial fibrillation patients and have lower incidence of major hemorrhagic complications.


• The addition of aspirin to anticoagulation may be indicated in patients who have concomitant coronary artery disease.

Historical note and terminology

As early as 1628, Harvey had observed undulation in the right atrium of a dying animal heart (McMichael 1982); in 1874, Vulpian reported uncoordinated twitching of the atrium, "fremissement fibrillaire" after application of an electrical current (Vulpian 1874). Nothnagel published 3 arterial pulse curves showing irregular heart rates in the mid-1800s and called the arrhythmia "delirium cordis" (Nothnagel 1876), which was defined by the complete irregularity of heartbeats continuously changing in "height and tension." However, the association between these atrial fibrillary contractions and the irregular pulse was not formally made until 1907 (Cushny 1907).

In 1940, Karl Paul Link synthesized dicumarol, a substance found in spoiled sweet clover known to cause a hemorrhagic disease in cattle; in 1947, its use was advocated for the prevention of cardiac embolism in patients with rheumatic atrial fibrillation (Wright 1947). However, the risk of stroke in patients with chronic nonvalvular atrial fibrillation was generally believed to be too small to require medication. It was not until 1978 that the results of the Framingham Study clearly demonstrated an increase in stroke incidence in patients with chronic nonrheumatic atrial fibrillation (Wolf et al 1978). Vitamin K antagonists, including warfarin, have been the treatment of choice for the prevention of stroke or systemic embolism in patients with atrial fibrillation for many decades. More recently, however, large randomized placebo-control studies demonstrated the efficacy and safety of different non-vitamin K antagonists or novel oral anticoagulants in the treatment of nonvalvular atrial fibrillation.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology